von Willebrand disease

(redirected from Willebrand disease)
Also found in: Medical.

von Wil·le·brand disease

 (vŏn wĭl′ə-brănd′, fôn vĭl′ə-bränt′)
A usually genetic bleeding disorder caused a deficiency or an abnormality of a clotting factor that affects platelet adhesion.

[After Erik Adolf von Willebrand (1870-1949), Finnish physician.]
References in periodicals archive ?
Contract awarded for Summary of contract results: itb 56-2017-undp-ukr procurement of medicines for treatment of adults with hemophilia and children with hemophilia a or b or willebrand disease and medicines for emergency medical care in case of bleeding for the national public health programme to theministry of health (moh) in ukraine.
The most common IBD is von Willebrand disease (vWD), which affects both platelet adhesion to the vessel wall and factor VIII levels, and may therefore present with a mixed bleeding profile.
M2 EQUITYBITES-June 22, 2017-Shire receives EMA validation for MAA of VEYVONDI to treat von Willebrand Disease
M2 PHARMA-June 22, 2017-Shire receives EMA validation for MAA of VEYVONDI to treat von Willebrand Disease
In a statement, Villanueva said the country's health care system remains ill-equipped in handling bleeding disorders, including hemophilia and the Von Willebrand Disease.
Objective: To determine the frequency of Von Willebrand disease (vWD) in patients of heavy menstrual bleeding (HMB).
Low factor VIII (FVIII) [2] concentrations are associated with hemophilia A, type 2N von Willebrand disease (vWD), and combined factor V/VIII (CFV/VIII) deficiency.
They research, develop, manufacture and market biotherapies, which are used to treat serious and rare conditions, including coagulation (bleeding) disorders such as haemophilia and von Willebrand disease and immune deficiencies.
The former Moor End High School and Greenhead College student suffers from a severe bleeding condition called Von Willebrand disease type 3, causing her to spontaneously bleed.
In December, for example, the Food and Drug Administration approved the first recombinant von Willebrand factor to treat bleeding episodes in adults diagnosed with von Willebrand disease (VWD).
sup][3] Therefore, in addition to the treatment of congenital bleeding disorders, such as mild hemophilia A and von Willebrand disease, DDAVP can also be used in clinical practice to treat the bleeding caused by abnormal PLT function after cardiac surgery with CPB.